Browse > Article
http://dx.doi.org/10.5125/jkaoms.2013.39.5.246

Importance of immediate surgical intervention and antifungal treatment for rhinocerebral mucormycosis: a case report  

Kim, Jin-Geun (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University)
Park, Hye Jeong (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University)
Park, Jung Hyun (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University)
Baek, Jiwoong (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University)
Kim, Hyung Jun (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University)
Cha, In-Ho (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University)
Nam, Woong (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University)
Publication Information
Journal of the Korean Association of Oral and Maxillofacial Surgeons / v.39, no.5, 2013 , pp. 246-250 More about this Journal
Abstract
Rhinocerebral mucormycosis (RCM) is an opportunistic, potentially life-threatening fungal disease. This infective disease invades not only the facial sinuses, but also the maxilla, zygoma, and rhino-cerebral structures with a massive destruction of the facial skeletons and soft tissue. This disease progresses within various underlying diseases, such as diabetes mellitus, hematologic malignancy, renal failure, and systemic immunodepression. The relationship between mucormycosis and these underlying conditions have been discussed extensively in the literature. The authors studied 6 cases of RCM diagnosed by a tissue biopsy and treated at the department of oral and maxillofacial surgery, from 1997 to 2012. Patients were treated with several kinds of surgical interventions and antifungal agents, and their clinical & radiological signs, underlying conditions, surgical methods, and outcomes were analyzed.
Keywords
Mucormycosis; Diabetes mellitus; Diagnosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Abu El-Naaj I, Leiser Y, Wolff A, Peled M. The surgical management of rhinocerebral mucormycosis. J Craniomaxillofac Surg 2013;41:291-5.   DOI
2 Mantadakis E, Samonis G. Clinical presentation of zygomycosis. Clin Microbiol Infect 2009;15(Suppl 5):15-20.
3 Dhiwakar M, Thakar A, Bahadur S. Improving outcomes in rhinocerebral mucormycosis--early diagnostic pointers and prognostic factors. J Laryngol Otol 2003;117:861-5.
4 Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009;15:1395-401.   DOI
5 Rammaert B, Lanternier F, Poirée S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab 2012;38:193-204.   DOI
6 Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982;38:1123-9.
7 Llorente A, Perez-Valero I, García E, Heras I, Fraile V, García P, et al. Mortality risk factors in patients with zygomycosis: a retrospective and multicentre study of 25 cases. Enferm Infecc Microbiol Clin 2011;29:263-8.   DOI
8 Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53.   DOI
9 Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006;44:335-42.   DOI
10 Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012;50:611-8.   DOI
11 Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, et al; GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Infection Program. Mucormycosis in hematologic patients. Haematologica 2004;89:207-14.
12 Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47:503-9.   DOI
13 Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon. Clin Microbiol Infect 2009;15(Suppl 5):98-102.
14 Gamaletsou MN, Sipsas NV, Roilides E, Walsh TJ. Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep 2012;14:423-34.   DOI
15 Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47:364-71.   DOI
16 Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000;182:274-82.   DOI